Literature DB >> 22653979

Pioglitazone and the risk of bladder cancer.

Dominique Hillaire-Buys, Jean-Luc Faillie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22653979     DOI： 10.1136/bmj.e3500

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  7 in total

1.  An Automated System Combining Safety Signal Detection and Prioritization from Healthcare Databases: A Pilot Study.

Authors:  Mickael Arnaud; Bernard Bégaud; Frantz Thiessard; Quentin Jarrion; Julien Bezin; Antoine Pariente; Francesco Salvo
Journal:  Drug Saf       Date:  2018-04       Impact factor: 5.606

2.  Cardioprotective Effects of Pioglitazone in Type 2 Diabetes.

Authors:  Devjit Tripathy; Carolina Solis-Herrera; Robert E J Ryder
Journal:  Diabetes Spectr       Date:  2021-08-18

Review 3.  Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis.

Authors:  Cristina Bosetti; Valentina Rosato; Danilo Buniato; Antonella Zambon; Carlo La Vecchia; Giovanni Corrao
Journal:  Oncologist       Date:  2013-01-23

4.  Fibrates and risk of cancer in tissues with high PPAR-α concentration: a nested case-control study.

Authors:  Francesco Salvo; Fabienne Bazin; Aude Kostrzewa; Christian Bandre; Philip Robinson; Nicholas Moore; Bernard Bégaud; Antoine Pariente
Journal:  Drug Saf       Date:  2014-05       Impact factor: 5.606

5.  Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries.

Authors:  Pasi Korhonen; Edith M Heintjes; Rachael Williams; Fabian Hoti; Solomon Christopher; Maila Majak; Leanne Kool-Houweling; Helen Strongman; Marie Linder; Paul Dolin; Shahram Bahmanyar
Journal:  BMJ       Date:  2016-08-16

Review 6.  Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis.

Authors:  Elena Filipova; Katya Uzunova; Krassimir Kalinov; Toni Vekov
Journal:  Diabetes Ther       Date:  2017-06-16       Impact factor: 2.945

7.  Pathology of bladder cancer among diabetic patients undergoing radical cystectomy with a history of pioglitazone (Actos) use.

Authors:  Victoriano Romero; Charles Peyton; Ian Gray; Ashok Hemal; Ryan Terlecki
Journal:  BMC Urol       Date:  2014-01-25       Impact factor: 2.264
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.